Portal de Periódicos da CAPES

Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer

2021; The Japanese Society of Internal Medicine; Volume: 60; Issue: 22 Linguagem: Inglês

10.2169/internalmedicine.6410-20

1349-7235

Ryota Ushio, Masaki Yamamoto, Atsushi Miyasaka, Tatsuya Muraoka, Hiromi Kanaoka, Hironori Tamura, Ayami Kaneko, Ami Izawa, Nobuyuki Hirama, Shuhei Teranishi, Saki Manabe, Tatsuya Inoue, Kunihiko Shibata, Yasuyuki Sugiura, Makoto Kudo, Takeshi Kaneko,

Myasthenia Gravis and Thymoma

A 58-year-old man was diagnosed with lung adenocarcinoma with a tumor proportion score of 10%. After six cycles of second-line chemotherapy with nivolumab, he achieved a complete response (CR) but developed uveitis and sensorineural hearing disorder, which were consistent with Vogt-Koyanagi-Harada (VKH)-like syndrome. Simultaneously, pituitary adrenocortical insufficiency was identified. Nivolumab discontinuation and systemic corticosteroid administration resolved these immune-related adverse events (irAEs). The patient has maintained a CR without any chemotherapy for approximately two years. We herein report a patient with a long-term progression-free survival despite chemotherapy discontinuation due to irAEs, including VKH-like syndrome, which were appropriately managed.